News › Industry News, News

ITC Favors Allergan Partner Medytox Over Daewoong in Botulinum Toxin Strain Dispute

July 10, 2020

The U.S. International Trade Commission (ITC) has sided with South Korean drugmaker Medytox Inc. in a dispute, saying its local rival Daewoong Pharmaceutical Co. stole trade secrets on a botulinum toxin strain, industry officials here said Tuesday.
In its preliminary verdict, the ITC also advised that imports of Daewoong Pharmaceutical’s botulinum toxin products be banned in the United States over the next 10 years.Read more at the Yonhap News Agency >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Retatrutide Phase 3 Trial: Adults With Type 2 Diabetes Lost Average of 50 Pounds
    • Medical Marketing Whiz Recognized With Healthcare Digital Marketing Excellence Award
    • Allergan Presents Early Data on Skin Quality Treatments for Patients Taking Weight-Loss Medications
    • ValueCap Becomes Silver Vendor Affiliate with the American Med Spa Association
    • FDA Warning Letter Signals Increased Scrutiny of the Medical Necessity Exception for Compounded GLP-1s
Advertisement